Introduction

The European CDMO market news summary for the final quarter of 2025 reveals a sector operating at peak intensity. Contract Development and Manufacturing Organizations (CDMOs) across the continent are currently executing the largest infrastructure build-outs in a generation. Driven by the “GLP-1 gold rush,” the rise of antibody-drug conjugates (ADCs), and the European Union’s push for “Health Sovereignty,” the landscape is shifting from a service-based model to a strategic partnership model. This month, we have seen billion-euro investments from Swiss giants, strategic realignments in France, and a digital overhaul of German manufacturing plants. These movements signify a region that is prioritizing high-value, complex modalities to maintain its global competitive edge against emerging markets.

The Peptide Revolution: CordenPharma’s Billion-Euro Gambit

CordenPharma has dominated headlines this month by confirming its status as a leader in the peptide space. The company announced a record-breaking investment exceeding €1 billion to expand its peptide platform. This move specifically targets the massive global demand for GLP-1 agonists used in treating obesity and diabetes. The heart of this expansion is a new greenfield facility in Muttenz, Switzerland.

This facility is not just an incremental update; it is a massive scaling of solid-phase peptide synthesis (SPPS) capacity. The site will house several 3,000-liter reactors, bringing the total SPPS capacity of the company to over 30,000 liters. This scale allows pharmaceutical innovators to transition from clinical trials to global commercial supply without changing partners. CordenPharma’s CEO emphasized that these investments are backed by long-term customer contracts, ensuring the company hits its €1 billion revenue target for peptides by 2028.

Beyond Switzerland, CordenPharma is also upgrading its sites in France and Italy. These upgrades focus on small-molecule drug substances and highly potent APIs (HPAPIs). By diversifying its geographic footprint within Europe, the company mitigates regulatory risks and provides redundant supply chains for its partners. The integration of automated purification systems and high-throughput chromatography ensures that the purity levels meet the most stringent FDA and EMA standards.

Lonza’s Aseptic Dominance and the Stein Milestone

Lonza Group, the anchor of the Basel life sciences cluster, has achieved a critical regulatory milestone this month. Its new large-scale drug-product fill-finish facility in Stein, Switzerland, is now fully operational and has received initial GMP certifications. This CHF 500 million investment addresses one of the most significant bottlenecks in the biologics supply chain: sterile filling.

The Stein facility utilizes advanced isolator technology to handle highly potent biologics, including monoclonal antibodies and recombinant proteins. This “end-to-end” offering allows Lonza’s clients to manufacture the drug substance and the final drug product within the same regional network. This reduces the risk of cold-chain disruptions and simplifies the regulatory filing process.

Lonza’s recent quarterly report also highlights a surge in demand for its “Ibex Solutions” in Visp. This flexible manufacturing model allows biotech companies to “rent” dedicated capacity while leveraging Lonza’s existing infrastructure and expertise. As the market for ADCs grows, Lonza is also expanding its bioconjugation capacity in Switzerland to accommodate the complex chemistry required to link toxins to antibodies.

Siegfried and the Competitive Vacuum in Fill-Finish

The acquisition of Catalent by Novo Holdings has created a significant shift in the European CDMO ecosystem. As Novo Nordisk absorbs Catalent’s sites in Anagni, Italy, and Brussels, Belgium, for its own internal production, many “displaced” pharmaceutical companies are seeking new homes for their sterile injectables. Siegfried has emerged as a primary beneficiary of this market movement.

Siegfried’s Hameln site in Germany is currently seeing a record number of inquiries for its aseptic filling lines. To manage this growth, the company recently appointed Peter Freisler as Chief Business Officer. His mandate is to steer the “EVOLVE+” strategy, which prioritizes high-margin, specialized services over commodity manufacturing.

Siegfried is also making strategic moves in Spain. Its site in El Masnou is becoming a hub for ophthalmic drug production. By focusing on these niche delivery systems—such as eye drops and sterile ointments—Siegfried avoids the direct competition of large-scale biologics while maintaining high profitability. The company’s commitment to “dual-sourcing” strategies has made it a favorite for European firms looking to de-risk their supply chains away from a single-provider model.

France’s Focus on Sovereignty: The EUROAPI Transformation

In France, EUROAPI is undergoing a radical restructuring known as the “FOCUS-27” plan. This month, the company confirmed that it is successfully divesting its non-core sites to focus on high-value CDMO activities. EUROAPI, which spun off from Sanofi, is repositioning itself as a specialist in highly potent active pharmaceutical ingredients (HPAPIs) and complex small molecules.

The French government has played a pivotal role in this transformation. Through the “France 2030” initiative, EUROAPI has received significant public funding to modernize its sites in Vertolaye and Elbeuf. This funding supports the development of innovative manufacturing processes, such as continuous flow chemistry, which reduces environmental impact and improves yield.

EUROAPI is also strengthening its ties with European biotech startups. By providing early-phase development services, the company builds long-term relationships that transition into commercial contracts as these drugs move through the pipeline. The extension of shareholder lock-up agreements from Sanofi and Bpifrance this month provides the financial runway needed to complete this multi-year turnaround.

Germany’s IDT Biologika: From Vaccines to Advanced Therapeutics

IDT Biologika, based in Dessau-Roßlau, has completed its first full month under the strategic guidance of SK bioscience. This partnership has breathed new life into the German CDMO, which was a critical player during the COVID-19 pandemic. Today, the focus has shifted toward viral vectors and gene therapies.

IDT Biologika is currently expanding its capacity for “one-stop-shop” vaccine production. This includes everything from process development to large-scale drug substance synthesis and aseptic fill-finish. The company’s expertise in handling live viruses and complex biologics makes it a rare asset in the European market.

With the backing of SK bioscience, IDT is also looking to expand its footprint in North America, but its core manufacturing will remain in Germany. The company is currently hiring hundreds of scientists to staff its new R&D center, which focuses on improving the stability of mRNA-based treatments. This move aligns with the German government’s goal of making the country a “Global Health Hub” by 2030.

Sustainability and the Digital Twin Revolution

A major theme in this month’s news is the integration of “Industry 4.0” technologies across European sites. Saltigo, a subsidiary of LANXESS, is leading the charge in digital transformation. At its Leverkusen and Dormagen sites, Saltigo has implemented “Digital Twin” technology for its chemical reactors.

This technology allows engineers to simulate chemical reactions in a virtual environment before running them in the real world. This optimizes the use of raw materials, reduces energy consumption, and prevents batch failures. In the current European energy market, these efficiencies are critical for maintaining price competitiveness against Asian manufacturers.

Furthermore, sustainability is now a core part of the CDMO value proposition. Evonik recently announced that its Health Care business line is transitioning to 100% renewable electricity across all European sites. Evonik is also pioneering the use of plant-based lipids for mRNA delivery, replacing traditional synthetic lipids. This move appeals to the growing number of pharmaceutical companies that have committed to “Net Zero” targets.

Regulatory Shifts and the Critical Medicines Alliance

The European Medicines Agency (EMA) and the European Commission have introduced new guidelines this month aimed at strengthening the pharmaceutical supply chain. The “Critical Medicines Alliance” is now actively identifying essential drugs that are at risk of shortage. This list includes many antibiotics and oncology treatments that have historically been manufactured in China or India.

CDMOs like Recipharm and Aenova are positioning themselves to receive government incentives for “re-shoring” these products. By building dedicated lines for essential medicines, these companies ensure a steady stream of revenue while fulfilling a public health need. This regulatory tailwind is expected to drive steady growth in the small-molecule segment, which many analysts previously viewed as a stagnant part of the market.

Conclusion: A Resilient Future for European Manufacturing

The European CDMO market news summary for 2025 showcases a region that is reinventing itself. By focusing on the most difficult-to-manufacture modalities—peptides, biologics, and gene therapies—European CDMOs are securing their place in the future of medicine. The billion-euro investments from players like CordenPharma and Lonza are not just bets on individual drugs; they are bets on the long-term viability of Europe as a global manufacturing powerhouse.

As we move into 2026, the success of these organizations will depend on their ability to balance technological innovation with economic efficiency. The integration of AI, the commitment to green energy, and the agility to respond to market shifts like the Catalent acquisition will define the next decade of pharmaceutical production in Europe.

References and Citations:

1. CordenPharma Group. (2025). CordenPharma Invests €1 Billion in Peptide Platform. cordenpharma.com
2. Lonza Group. (2025). Lonza Completes Stein Drug Product Facility. lonza.com
3. Siegfried Holding AG. (2025). Siegfried Appoints New CBO and Updates Strategy. siegfried.ch
4. EUROAPI. (2025). FOCUS-27 Strategic Update and Divestitures. euroapi.com
5. IDT Biologika. (2025). Expansion of Viral Vector and Vaccine Capacity. idt-biologika.com
6. Saltigo (LANXESS). (2025). Digital Transformation in Chemical Synthesis. lanxess.com
7. DCAT Value Chain Insights. (2025). Global CDMO Market Trends and Capacity Shifts. dcatvci.org
8. Evonik Industries. (2025). Sustainable Lipid Production for mRNA. evonik.com